Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
Wed, 2 Dec 2009 19:35:00 GMT
Company's efforts to further the clinical development of Tovaxin, Opexa's flagship therapy for MS. Additionally, Dawn McGuire, M.D., Opexa's expert clinical advisor and member of the Company's Clinical Advisory Board has agreed to further increase her
more